Home › Funds › ORBIMED ADVISORS LLC › NKTR

ORBIMED ADVISORS LLC position in NKTR

NEKTAR THERAPEUTICS · Health Care

ORBIMED ADVISORS LLC reported holding 465,346 shares of NKTR (NEKTAR THERAPEUTICS) in its Q2 2026 13F filing — a position valued at US$32.5M, representing 0.65% of its reported portfolio and ranking #42 among its reported holdings. ORBIMED ADVISORS LLC has disclosed NKTR holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

Latest position (Q2 2026)465.35K sh
Reported value held$32.49M
Portfolio Weight0.65%
First reportedQ1 2026
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ORBIMED ADVISORS LLC's NKTR position evolved

ORBIMED ADVISORS LLC first disclosed a stake in NKTR in Q1 2026 at 275,000 shares (US$19.8M). The position peaked in Q2 2026 at 465,346 shares, worth US$32.5M. Across 2 filings, ORBIMED ADVISORS LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 465,346 shares valued at US$32.5M — an increase of 190,346 shares quarter over quarter.. Notable position changes include a 69% increase in Q2 2026 (shares fell 13% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2026 275.00K $19.79M New
Q2 2026 465.35K $32.49M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NKTR and 13F data

NKTR (NEKTAR THERAPEUTICS) is a Health Care company. 70 other funds we track also report a position in NKTR — the largest reported positions include Two Seas Capital LP (US$202.6M), BVF INC/IL (US$166.9M), Vestal Point Capital, LP (US$69.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NKTR

All NKTR fund holders →

FAQ

How long has ORBIMED ADVISORS LLC held NKTR?

ORBIMED ADVISORS LLC has disclosed NKTR holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

What is ORBIMED ADVISORS LLC's current position in NKTR?

As of Q2 2026, ORBIMED ADVISORS LLC holds 465.35K shares of NKTR (NEKTAR THERAPEUTICS), valued at $32.49M, representing 0.65% of its reported portfolio and ranking #42.

Has ORBIMED ADVISORS LLC been buying or selling NKTR?

In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC increased its position in NKTR. The position peaked in Q2 2026 at 465.35K shares.

Which other funds hold NKTR?

Other major institutional holders of NKTR include Two Seas Capital LP, BVF INC/IL, Vestal Point Capital, LP, among 70 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.